UroGen Pharma Ltd Newsroom

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

BenzingaDec 6 20:16 · Ratings

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen PharmaDec 6 13:00

UroGen Pharma Announces UGN-102 Long-Term Results In The Phase 3 ENVISION Trial, Potentially Paving The Way For First FDA-Approved Treatment For LG-IR-NMIBC; UGN-102 Demonstrated 82.3% Duration Of Response At 12 Months In Patients Who Achieved...

BenzingaDec 6 04:18

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UroGen PharmaDec 5 13:00

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

UroGen PharmaDec 2 13:00

UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO

BenzingaNov 26 21:09

New Data From a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response With JELMYTO

UroGen PharmaNov 26 13:00

Further Weakness as UroGen Pharma (NASDAQ:URGN) Drops 13% This Week, Taking Five-year Losses to 64%

Simply Wall StNov 18 19:14

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 7 06:21 · Conference Call

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsNov 7 06:12

TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $35

Futu NewsNov 7 04:31 · Ratings

EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Analyst UpgradesNov 7 00:19

UroGen Pharma Analyst Ratings

BenzingaNov 7 00:19 · Ratings

UroGen Pharma Ltd | 10-Q: Q3 2024 Earnings Report

SECNov 6 21:07 · Announcements

UroGen Pharma Ltd | 8-K: UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

SECNov 6 21:07

UroGen Pharma Expects Full-year 2024 JELMYTO Revenue To Be Below The Low End Of Previously Provided Guidance Range

BenzingaNov 6 21:05

UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate

BenzingaNov 6 21:01

Press Release: UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Dow JonesNov 6 21:00

UroGen Pharma 3Q Loss $23.7M >URGN

Dow JonesNov 6 21:00

UroGen Pharma 3Q Loss/Shr 55c >URGN

Dow JonesNov 6 21:00